Drug reference

Rufinamide

Antiseizure agent (triazole derivative) · Antiepileptic

START

400–800 mg/day in 2 divided doses with food

TYPICAL MAX

3200 mg/day

STOP IF

Severe skin reaction (DRESS/SJS), suicidality, or status epilepticus

WATCH

Skin, ECG (short QT) if at-risk, mood; do not stop abruptly

CDSCO approvedSchedule HATC N03AF03

Dose laddermg/d

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 2h · absorption
PEAK: 5h · Tmax fed
t½: 8h · t½
DURATION: 12h · twice-daily

EXCRETION

Renal — metabolites

route + CYP

INTERACTIONS

5 major

SEVERE in our sources

PREGNANCY

Use only if benefit outweighs risk (antiseizure-drug fetal risk class).

FDA category + note

Top interactionssee all 5 →

BuprenorphineSevereDatabaseDDInter
DextropropoxypheneSevereDatabaseDDInter
LevacetylmethadolSevereDatabaseDDInter
LumateperoneSevereDatabaseDDInter

Mechanism

Modulates voltage-gated sodium channels, prolonging the inactive state and reducing sustained, repetitive neuronal firing — effective against multifocal drop attacks of Lennox–Gastaut syndrome.

Indications

Adjunctive treatment of seizures associated with Lennox–Gastaut syndrome (≥1 y)

Dosing

Adult: 400–800 mg/day in 2 divided doses, titrate by 400–800 mg/day every 2 days as tolerated; target 3200 mg/day (or 45 mg/kg/day in lower-weight).
Pediatric: ≥1 y: 10 mg/kg/day in 2 divided doses, titrate to 45 mg/kg/day (max 3200 mg/day).
Renal adjustment: No adjustment (renal contribution minor).
Hepatic adjustment: Mild–moderate: no adjustment; severe: not recommended.
Geriatric: Limited data; titrate cautiously.
Max dose: 3200 mg/day